NMIBC Treatment Landscape

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Janet Kukreja, MD, MPH, FACS

CME Available: auau.auanet.org/node/44076

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

AstraZeneca

Johnson & Johnson

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.

2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.

3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.